Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson's group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research.
Cynata's Cymerus™ platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohn’s disease and heart disease. Cynata’s proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.
Cynata will use the proprietary Cymerus™ technology to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for the Company.
The Cymerus™ technology has several characteristics which makes it ideal for the development of cell-based therapeutics. Most critically, the Cymerus™ manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities. This means that Cynata will not have to constantly seek out fresh stem cell donors to fuel its manufacturing demands. This has the potential to create a new standard in the emergent arena of regenerative medicine and stem cell therapeutics and provides Cynata with both a unique differentiator and an important competitive position.
Cynata's Cymerus™ platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohn’s disease and heart disease. Cynata’s proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.
Cynata will use the proprietary Cymerus™ technology to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for the Company.
The Cymerus™ technology has several characteristics which makes it ideal for the development of cell-based therapeutics. Most critically, the Cymerus™ manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities. This means that Cynata will not have to constantly seek out fresh stem cell donors to fuel its manufacturing demands. This has the potential to create a new standard in the emergent arena of regenerative medicine and stem cell therapeutics and provides Cynata with both a unique differentiator and an important competitive position.
Location: Australia
Employees: 1-10
Total raised: $15M
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Bioscience... | bioscience... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.12.2020 | - | $15M | Bioscience... |
Mentions in press and media 8
| Date | Title | Description |
| 15.12.2025 | Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial | Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom ... |
| 05.12.2024 | CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial | MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfull... |
| 23.05.2024 | Further CYP-001 GvHD Clinical Data Published in Nature Medicine | Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60% MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a cl... |
| 08.04.2024 | Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial | MELBOURNE, Australia, April 8, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to ... |
| 02.03.2021 | New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs | MELBOURNE, Australia, March 02, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the initiation of a... |
| 01.03.2021 | Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte | MELBOURNE, Australia, March 01, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a ... |
| 11.12.2020 | Cynata Therapeutics : Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline | MELBOURNE, Australia, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 ... |
| 11.12.2020 | CYNATA THERAPEUTICS LIMITED Cynata Therapeutics : Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline | MELBOURNE, Australia, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 ... |